TY - JOUR
T1 - Episignature analysis of moderate effects and mosaics
AU - Oexle, Konrad
AU - Zech, Michael
AU - Stühn, Lara G.
AU - Siegert, Sandy
AU - Brunet, Theresa
AU - Schmidt, Wolfgang M.
AU - Wagner, Matias
AU - Schmidt, Axel
AU - Engels, Hartmut
AU - Tilch, Erik
AU - Monestier, Olivier
AU - Destrėe, Anne
AU - Hanker, Britta
AU - Boesch, Sylvia
AU - Jech, Robert
AU - Berutti, Riccardo
AU - Kaiser, Frank
AU - Haslinger, Bernhard
AU - Haack, Tobias B.
AU - Garavaglia, Barbara
AU - Krawitz, Peter
AU - Winkelmann, Juliane
AU - Mirza-Schreiber, Nazanin
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/9
Y1 - 2023/9
N2 - DNA methylation classifiers (“episignatures”) help to determine the pathogenicity of variants of uncertain significance (VUS). However, their sensitivity is limited due to their training on unambiguous cases with strong-effect variants so that the classification of variants with reduced effect size or in mosaic state may fail. Moreover, episignature evaluation of mosaics as a function of their degree of mosaicism has not been developed so far. We improved episignatures with respect to three categories. Applying (i) minimum-redundancy-maximum-relevance feature selection we reduced their length by up to one order of magnitude without loss of accuracy. Performing (ii) repeated re-training of a support vector machine classifier by step-wise inclusion of cases in the training set that reached probability scores larger than 0.5, we increased the sensitivity of the episignature-classifiers by 30%. In the newly diagnosed patients we confirmed the association between DNA methylation aberration and age at onset of KMT2B-deficient dystonia. Moreover, we found evidence for allelic series, including KMT2B-variants with moderate effects and comparatively mild phenotypes such as late-onset focal dystonia. Retrained classifiers also can detect mosaics that previously remained below the 0.5-threshold, as we showed for KMT2D-associated Kabuki syndrome. Conversely, episignature-classifiers are able to revoke erroneous exome calls of mosaicism, as we demonstrated by (iii) comparing presumed mosaic cases with a distribution of artificial in silico-mosaics that represented all the possible variation in degree of mosaicism, variant read sampling and methylation analysis. [Figure not available: see fulltext.].
AB - DNA methylation classifiers (“episignatures”) help to determine the pathogenicity of variants of uncertain significance (VUS). However, their sensitivity is limited due to their training on unambiguous cases with strong-effect variants so that the classification of variants with reduced effect size or in mosaic state may fail. Moreover, episignature evaluation of mosaics as a function of their degree of mosaicism has not been developed so far. We improved episignatures with respect to three categories. Applying (i) minimum-redundancy-maximum-relevance feature selection we reduced their length by up to one order of magnitude without loss of accuracy. Performing (ii) repeated re-training of a support vector machine classifier by step-wise inclusion of cases in the training set that reached probability scores larger than 0.5, we increased the sensitivity of the episignature-classifiers by 30%. In the newly diagnosed patients we confirmed the association between DNA methylation aberration and age at onset of KMT2B-deficient dystonia. Moreover, we found evidence for allelic series, including KMT2B-variants with moderate effects and comparatively mild phenotypes such as late-onset focal dystonia. Retrained classifiers also can detect mosaics that previously remained below the 0.5-threshold, as we showed for KMT2D-associated Kabuki syndrome. Conversely, episignature-classifiers are able to revoke erroneous exome calls of mosaicism, as we demonstrated by (iii) comparing presumed mosaic cases with a distribution of artificial in silico-mosaics that represented all the possible variation in degree of mosaicism, variant read sampling and methylation analysis. [Figure not available: see fulltext.].
UR - http://www.scopus.com/inward/record.url?scp=85162855988&partnerID=8YFLogxK
U2 - 10.1038/s41431-023-01406-9
DO - 10.1038/s41431-023-01406-9
M3 - Article
AN - SCOPUS:85162855988
SN - 1018-4813
VL - 31
SP - 1032
EP - 1039
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 9
ER -